Cell- and peptide-based immunotherapeutic approaches for glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-04-09 / Trends Mol Med 2008 May;14(5):228-35Immunotherapy of hematological malignancies using dendritic cells
/in Dendritic Cells, International Publications, Malignant Lymphoma, Multiple Myeloma /von 2008-03-01 / Bull Cancer 2008 Mar;95(3):320-6Dendritic cell vaccines in melanoma: from promise to proof?
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-02-08 / Crit. Rev. Oncol. Hematol. 2008 May;66(2):118-34Immunotherapy opportunities in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2008-02-01 / Expert Rev Anticancer Ther 2008 Feb;8(2):243-57Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-16Delivery of whole tumor lysate into dendritic cells for cancer vaccination
/in Dendritic Cells, Hypernephroma, International Publications, NSCLC /von 2008-01-01 / Methods Mol. Biol. 2008;423:139-53Dendritic cell immunotherapy for malignant gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-01-01 / Rev Recent Clin Trials 2008 Jan;3(1):10-21A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
/in Dendritic Cells, Gallbladder Cancer, International Publications, Pancreatic Cancer /von 2008-01-01 / Cancer Ther 2008;6(B):955-964Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation
/in Dendritic Cells, International Publications /von 2007-12-21 / J. Leukoc. Biol. 2008 Mar;83(3):742-54
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution